A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.
Part of paid clinical trials in Newnan, Georgia.
- Sponsor
- AstraZeneca
- Study ID
- NCT02734004
- Phase
- PHASE1/PHASE2
- Status
- Active Not Recruiting
Conditions
- Breast
- Gastric Cancers
- Ovarian
- SCLC
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 130 Years
- Healthy Volunteers
- Not accepted
Interventions
- Olaparib — DRUGOlaparib
- MEDI4736 — DRUGMEDI4736
- Bevacizumab — DRUGBevacizumab
Study Details
The purpose of this study is to look at the effectiveness, safety, and antitumor activity of study drugs MEDI4736 in combination with olaparib (modules 1, 2, 3, 4, 5 and 7) and MEDI4736 in combination with olaparib and bevacizumab (module 6). It will also examine what happens to the study drugs in the body and investigate how well the combination between MEDI4736, olaparib and bevacizumab is tolerated.
Key Dates
- Start date
- Mar 17, 2016
- Status verified
- Apr 2026
- Primary completion
- Sep 17, 2021
- Completion
- Sep 17, 2026
Study Design
- Enrollment
- 264 participants (actual)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Arm 1Includes initial stage cohorts (modules 1 to 4): Olaparib twice daily starting on week 1 day 1 and MEDI4736 every 4 weeks starting on week 5 day 1
- Experimental: Arm 2Includes 2nd stage cohorts (modules 5 \& 7): Olaparib twice daily starting on week 1 day 1 and MEDI4736 every 4 weeks starting on week 1 day 1
- Experimental: Arm 3Includes 2nd stage cohort (module 6): Olaparib twice daily starting on week 1 day 1 / MEDI4736 every 4 weeks starting on week 1 day 1 / Bevacizumab every 2 weeks starting on week 1 day 1
Primary Outcome Measure
Initial Stage Cohorts: Disease Control Rate (DCR) at Week 12 [ Time Frame: RECIST performed at baseline, at 4 weeks after first dose of olaparib monotherapy and every 8 weeks +/-7 days thereafter. Assessed until DCO 14 Jun 2019. ]
Locations (7)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Research Site | Newnan | Georgia | 30265 | - |
| Research Site | Towson | Maryland | 21204 | - |
| Research Site | Boston | Massachusetts | 02114 | - |
| Research Site | Detroit | Michigan | 48202 | - |
| Research Site | St Louis | Missouri | 63110 | - |
| Research Site | Hilliard | Ohio | 43026 | - |
| Research Site | Philadelphia | Pennsylvania | 19104 | - |
Find similar trials in Newnan, GA
By condition
By specialty
Related Studies
- The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)PHASE1/PHASE2 · Recruiting · PMV Pharmaceuticals, Inc · Irvine, California
- GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2PHASE1 · Recruiting · Y-mAbs Therapeutics · Scottsdale, Arizona
- MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung CancerPHASE2 · Recruiting · Hirva Mamdani · Indianapolis, Indiana
- A Study of ZL-1310 in Subjects With Small Cell Lung CancerPHASE1 · Recruiting · Zai Lab (Shanghai) Co., Ltd. · Duarte, California